Nsclc 2nd line
Upcoming SlideShare
Loading in...5
×
 

Nsclc 2nd line

on

  • 893 views

 

Statistics

Views

Total Views
893
Views on SlideShare
893
Embed Views
0

Actions

Likes
0
Downloads
29
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Nsclc 2nd line Nsclc 2nd line Presentation Transcript

  • Second Line Treatment of metastatic Non-Small Cell Lung Cancer Update from the World Conference on Lung Cancer G. Nsouli MDTuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Weekly vs 3-weekly Docetaxel Overall survival (OAS) curves by treatment arm. Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second- Line Treatment of Advanced Non– Small-Cell Lung Cancer Di MaioTuesday, August 9, 2011 J.Clin. Oncol.
  • Weekly vs 3-weekly Docetaxel Treatment effect on survival within major patient subgroups. PS, performance status. Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second- Line Treatment of Advanced Non– Small-Cell Lung Cancer Di MaioTuesday, August 9, 2011 J.Clin. Oncol.
  • Pemetrexed vs. Docetaxel in second line Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non– Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97Tuesday, August 9, 2011
  • Survival and Toxicity Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non– Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97Tuesday, August 9, 2011
  • Median time to progression (A) for patients younger than 70 years of age: pemetrexed, 3.0 months v docetaxel, 3.9 months (hazard ratio [HR], 1.03; ; (B) for patients 70 years of age: pemetre-xed, 4.6 months v docetaxel, 2.9 months (HR,Benefit0.72; Elderly Patients From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non– Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11Tuesday, August 9, 2011
  • Median overall survival time (A) for patients younger than 70 years of age: pemetrexed, 7.8 months v docetaxel, 8.0 months HR], 1.02; (B) for patients 70 years of age: pemetrexed, 9.5 months v docetaxel, 7.7 months (HR, 0.86; Patients Benefit Elderly From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non– Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11Tuesday, August 9, 2011
  • Current Guidelines in Second line treatment of NSCLC • For patients with disseminated metastatic disease, both second-line cytotoxic chemotherapy and small molecule epidermal growth factor receptor (EGFR) inhibitors may provide palliation and increase survival. • When symptoms are due to progressive disease within the chest or from metastatic involvement of a single or limited number of sites, radiation therapy (RT) is often useful for palliation.Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011
  • Tuesday, August 9, 2011